title: Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
authors.forename: B
authors.initials: B
authors.lastname: Legras
authors.forename: C
authors.initials: C
authors.lastname: Clerc
authors.forename: A
authors.initials: A
authors.lastname: Ruelland
authors.forename: G
authors.initials: G
authors.lastname: Doualin
authors.forename: V
authors.initials: V
authors.lastname: Fertil
authors.forename: L
authors.initials: L
authors.lastname: Cloarec
mesh_terms: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000172:deficiency*; D001629:Bezafibrate / Q000009:adverse effects / Q000627:therapeutic use; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D058607:Fibric Acids; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008075:Lipoproteins, HDL / Q000172:deficiency*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D002995:Clofibric Acid; C019304:ciprofibrate; D011341:Probucol; D001629:Bezafibrate